GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (LSE:HIK) » Definitions » Institutional Ownership

Hikma Pharmaceuticals (LSE:HIK) Institutional Ownership : 37.85% (As of Oct. 31, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Hikma Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Hikma Pharmaceuticals's institutional ownership is 37.85%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Hikma Pharmaceuticals's Insider Ownership is 17.55%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Hikma Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 0.00%.


Hikma Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for Hikma Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Institutional Ownership Chart

Hikma Pharmaceuticals Historical Data

The historical data trend for Hikma Pharmaceuticals can be seen below:

2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30 2024-05-31 2024-06-30 2024-07-31 2024-08-31 2024-09-30
Institutional Ownership 37.54 37.26 37.18 37.52 37.76 37.78 36.93 37.21 37.43 37.85

Hikma Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Hikma Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1 New Burlington Place, London, GBR, W1S 2HR
Hikma Pharmaceuticals PLC is engaged in developing, manufacturing, and marketing a broad range of generic, branded and non-branded, in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the revenue for the company is generated from its injectables segment under which it supplies hospitals across markets with generic injectable products, supported by its manufacturing facilities. Geographically, North America is the company's key revenue generating market followed by Middle East and North Africa, United Kingdom, Europe and the rest of the world.

Hikma Pharmaceuticals Headlines

No Headlines